6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 Integrase Inhibitors

Although an extensive body of scientific and patent literature exists describing the development of HIV-1 integrase (IN) inhibitors, Merck’s raltegravir and Gilead’s elvitegravir remain the only IN inhibitors FDA-approved for the treatment of AIDS. The emergence of raltegravir-resistant strains of H...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhao, Xue Zhi, Maddali, Kasthuraiah, Smith, Steven J., Métifiot, Mathieu, Johnson, Barry C., Marchand, Christophe, Hughes, Stephen H., Pommier, Yves, Burke, Terrence R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523327/
https://ncbi.nlm.nih.gov/pubmed/23149229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2012.10.088
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares